CCTG Clinical Trials
Public Trial Select
Member Trial Select
Protecting Cancer Patients from COVID-19In the race to find new ways to prevent and treat COVID-19, CCTG has launched an innovative clinical trial focussed on strengthening the immune system for one of the most vulnerable populations – cancer patients. More >> |
Recently Activated Trials
Member Links
CCTG Announces Initiation of IND.239CCTG has announced the commencement of a Phase II study of CFI-400945, an oral, first-in-class inhibitor of Polo-like Kinase 4 in combination with durvalumab, a PD-L1 checkpoint inhibitor, in patients with advanced or metastatic triple negative breast cancer. More >> |
Planned Trials
Committees Select
Group newsletter: CCTG Connection
June 24, 2020
 CCTG is pleased to announce that the 2020 CCTG IND Team Award has been awarded to the BCCA Vancouver Centre IND.234 trial team based on the centre's accrual metrics both overall and for this past year, local activation timelines, and compliance metrics. The team members include: Kim Chi, Manahil Sadiq, Julita Sienkiewicz, and Wendy Won. Read More |
Dr. Lillian Siu - 2020 Recipient of the International Women Who Conquer Cancer Mentorship AwardPublished: June 24, 2020Category: News  CCTG is very proud to announce that Dr. Lillian Siu, Princess Margaret Cancer Centre, has been chosen as the recipient of the 2020 International Women Who Conquer Cancer Mentorship Award. Dr. Siu is the director of the Phase I Program, co-director of the Bras and Family Drug Development Program, and clinical lead for the Tumor Immunotherapy Program at Princess Margaret and is Co-Chair of CCTG's Head and Neck Site Committee. She also holds the BMO Chair in Precision Genomics. Read More |
 Two CCTG researchers were recently awarded nearly $2 million from the Canadian Cancer Society and the Conquer Cancer-Breast Cancer Research Foundation to support conduct of CCTG Investigational New Drug trials. Read More |
May 20, 2020
 CO28: NEOadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer: The NEO Trial has been closed to accrual after successfully reaching the accrual goal. The purpose of this study is to find out the effects of chemotherapy followed by less invasive surgery on patients and their early rectal cancer. The approach of this trial will be considered a success if at least 65% of participants are able to keep the rectum. Read More |
Transitions in the CCTG Quality of Life Committee LeadershipPublished: May 20, 2020Category: Group updates  After 22 years in his position as QOL committee co-chair, Dr. Michael Brundage is stepping down, to be succeeded by Dr. Winson Cheung. Read More |
May 07, 2020
 The IND216 trial: Phase II Study of Buparlisib in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia, has been permanently closed. About the trial: Buparlisib has been shown to shrink tumours in animals. It has been studied in some people and seems promising but it is not clear if it can offer better results than standard treatment. The standard or usual treatment for this disease is chemotherapy, targeted therapy or radiation, either alone or in combination. Read More |
CCTG Genitourinary Disease Site Committee welcomes new chair and modality sub-chairsPublished: May 07, 2020Category: Group updates  The CCTG Genitourinary Disease Site Committee is very honoured to welcome the new chair and modality sub-chairs. Read More |
|
|
